SCHEMBL6527231

SCHEMBL6527231

[O-][S+](Cc1ccccc1)c1ncc[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.47
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
MTOR P42345 1/20 0.39
ADK P55263 1/20 0.39
NISCH Q9Y2I1 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
BLM P54132 1/20 0.39
PMP22 Q01453 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GRIN2B Q13224 2/20 0.34
ADRA1A P35348 3/20 0.33
GRIN2A Q12879 1/20 0.33
ADRA2A P08913 1/20 0.32
ADRA1D P25100 1/20 0.32
ADRA1B P35368 1/20 0.32
EPHX2 P34913 1/20 0.31
MET P08581 1/20 0.31
HTR2B P41595 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27364674 0.83 TAAR1 (0.45) TAAR1CYP2D6TSHRMTORADK
SCHEMBL27525402 0.83 CYP1A2 (0.39) TAAR1CYP2D6TSHRHSD17B10
SCHEMBL27357182 0.82 CDK8 (0.37) TAAR1SMN1; SMN2
SCHEMBL4935105 0.80 MAPT (0.40) TAAR1CYP2D6SMN1; SMN2
SCHEMBL27357185 0.80 ADRA2A (0.36) LMNASMN1; SMN2ADRA1AADRA2AADRA1D
SCHEMBL27342986 0.80 LMNA (0.37) TAAR1LMNASMN1; SMN2ADRA1AADRA2A
SCHEMBL9012315 0.79 BACE1 (0.42) TAAR1TSHRHSD17B10
SCHEMBL27341816 0.78 FGFR1 (0.43) TAAR1LMNASMN1; SMN2
SCHEMBL27343501 0.78 ACP3 (0.40) TAAR1HTR2B
SCHEMBL9012347 0.78 ATP4A (0.33) TAAR1MTORADKNISCHADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1058594-A Imidazo [4,5-C] pyridines osteoporosis agent AMERICAN HOME PROD (US) 1992-02-12 CN claimed
US-6906078-B2 Method of using (H+/K+) ATPase inhibitors as antiviral agents PHARMACIA CORPORATION (US) 2005-06-14 US disclosed
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents MOORMAN ALAN E (US) 2001-11-29 US disclosed
US-5945425-A ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE G.D. SEARLE & CO. (US) 1999-08-31 US disclosed
WO-1995029897-A1 METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS G.D. SEARLE & CO. (US) 1995-11-09 WO disclosed
CN-1020902-C IMIDAZOLE DERIVATIVE AND PROCESSES FOR PREPARING SAME TANAHBE SEIYAKU CO LTD (JP) 1993-05-26 CN disclosed
CN-1058594-A Imidazo [4,5-C] pyridines osteoporosis agent AMERICAN HOME PROD (US) 1992-02-12 CN disclosed
CN-87108111-A Novel imidazole derivative and preparation method thereof 1988-09-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010047038-A1 Method of using (H+/K+) ATPase inhibitors as antiviral agents ATP4A, ATP1A1, ATP1A4 TAAR1 1705/4885CYP2D6 707/4885TSHR 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.